Johnson & Johnson News

Aktie
WKN:  853260 ISIN:  US4781601046 US-Symbol:  JNJ Branche:  Pharmazeutika Land:  USA
193,42 €
+2,18 €
+1,14%
12:31:08 Uhr
Depot/Watchlist
Marktkapitalisierung *
425,07 Mrd. €
Streubesitz
24,80%
KGV
19,04
Dividende
4,57 EUR
Dividendenrendite
2,61%
Nachhaltigkeits-Score
64 %
Index-Zuordnung
Dow Jones Industrial Average
Weiter aufwärts? Long handeln - Jetzt mit Hebel 8,65: UQ5SZR
Werbung

Johnson & Johnson News

13.05.25 - Aktienwelt360
Konsum, Kaffee, Krisen: Diese Aktien trotzen jedem Trend
Man sitzt morgens am Küchentisch und liest Schlagzeilen zu Themen wie wirtschaftlicher Un­sicher­heit, den aktuellen Marktschwankungen und einer möglichen Rezessionsgefahr. ...
09.05.25 - PR Newswire
Icotrokinra results show significant skin clearance in patients with difficult-to-treat scalp and genital psoriasis
Icotrokinra results show significant skin clearance in patients with difficult-​to-treat scalp and genital psoriasis PR Newswire
05.05.25 - PR Newswire
TREMFYA® (guselkumab) delivers sustained clinical and endoscopic remission in ulcerative colitis through two years
TREMFYA® (guselkumab) delivers sustained clinical and endoscopic remission in ulcerative colitis through two years PR Newswire
05.05.25 - PR Newswire
TREMFYA® (guselkumab) positioned to become the first and only IL-23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeks
TREMFYA® (guselkumab) positioned to become the first and only IL-23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeks ...
02.05.25 - Aktienwelt360
Wie Gold nur besser: Warum diese Aktienkategorie Sicherheit und hohe Rendite bietet
Gold als sicherer Hafen? Der Goldpreis erreichte kürzlich ein neues Allzeithoch von 3.500 US-Dollar. Kein Wunder, denn die Ängste wegen Donald Trump im Weißen Haus lassen ...
30.04.25 - PR Newswire
Johnson & Johnson receives FDA approval for IMAAVY™ (nipocalimab-aahu), a new FcRn blocker offering long-lasting disease control in the broadest population of people living with generalized myasthenia gravis (gMG)
Johnson & Johnson receives FDA approval for IMAAVY™ (nipocalimab-​aahu), a new FcRn blocker offering long-​lasting disease control in the broadest population of people living with ...
26.04.25 - PR Newswire
Johnson & Johnson's TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC
Johnson & Johnson's TAR-200 monotherapy achieves high disease-​free survival of more than 80 percent in BCG-​unresponsive, high-risk papillary NMIBC PR Newswire
26.04.25 - PR Newswire
Johnson & Johnson's TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in patients with certain types of bladder cancer
Johnson & Johnson's TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in patients with certain types of bladder cancer PR ...

Newssuche

Videos

newspaper
20.04.26 -0,69%
Technical Trading: GBP Long im Trend
GBP/USD Long Typ: Open End Turbo WKN: VV7A4S Hebel: 10 Laufzeit: OpenEnd Einstieg: Market ... Mehr »